Basic Information
Hexyon
Regulatory Information
EMEA/H/C/002796
April 17, 2013
February 21, 2013
33
December 11, 2024
Company Information
France
82 Avenue Raspail 94250 Gentilly
SANOFI WINTHROP INDUSTRIE
Active Substances Detail
filamentous haemagglutininHaemophilus influenzae type B polysaccharide (polyribosylribitol phosphate)hepatitis B surface antigenpertussis toxoidpoliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cellspoliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cellspoliovirus (inactivated) type 3 (Saukett strain) produced on Vero cellstetanus proteintetanus toxoid adsorbed on aluminium hydroxide, hydratedDiphtheria toxoid
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Hexyon. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Hexyon. For practical information about using Hexyon, patients should read the package leaflet or contact their doctor or pharmacist.